Sciety Strengthens PeptiSystems’ Board with the Appointment of Nick Roelofs

Sciety is enhancing its portfolio company, PeptiSystems, by appointing Nick Roelofs to its board of directors. This strategic addition aims to bolster the company’s ability to scale its sales globally and forge strong industrial partnerships in advanced pharmaceutical manufacturing. This recruitment is part of Sciety’s strategy to actively provide specialized expertise to its portfolio companies.

Nick Roelofs was elected to PeptiSystems’ board at the company’s general meeting, following a nomination by Sciety. His international experience and commercial acumen align with PeptiSystems’ needs as the company’s technology is validated, the market expands rapidly, and the commercialization journey accelerates.

PeptiSystems develops innovative synthesis instruments for the efficient and large-scale manufacturing of peptide- and oligonucleotide-based drugs – a field with rapidly growing global demand.

Nick Roelofs brings over 40 years of international experience from leadership roles in the life science industry, with a particular focus on advanced analytical instruments, diagnostics, and the commercialization of research-intensive technologies. With a Ph.D. in chemistry, he has led growth journeys in several global life science tools companies, commercializing highly specialized technologies in international markets. As President of the Life Sciences Group at Agilent Technologies, he led a business unit with approximately $3 billion in revenue and was responsible for both organic growth and acquisitions, including the Swedish company Halo Genomics and the Danish company DAKO. At Bio-Rad Laboratories, he helped shape the company’s innovation strategy and market expansion. Nick has also advised Summa Equity and Nordic Capital, playing key roles in investments in companies such as Olink – including the sale to Thermo Fisher for SEK 34 billion.

“Nick brings an unusual combination of scientific expertise, international business experience, and strategic acumen. With his solid background in building and leading global operations, he will be a strong addition to PeptiSystems’ board. His experience will be particularly valuable as the company continues to grow internationally and meet the rapidly increasing demand for advanced manufacturing solutions in the peptide and oligonucleotide field,” says Andreas Lindblom, Managing Partner at Sciety.

“Nick has extensive experience in commercializing advanced instruments and knows what it takes to succeed internationally. His insights will be a concrete support in our continued growth journey and in the dialogue with strategic partners,” says Karin Granath, CEO of PeptiSystems.

About PeptiSystems

PeptiSystems is a biotechnology company that develops next-generation flow-based instruments for the synthesis of peptide and oligonucleotide drugs. With its patented technology, PeptiSystems’ instruments significantly reduce production times, improve synthesis control, and minimize raw material consumption – without compromising purity or yield. Thanks to its scalability, the company’s innovative synthesis instruments can be easily adapted from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden.

About Sciety

Sciety is a leading investment company, focusing on the Nordic region. We work to ensure that innovative companies in life science and digital health grow and become successful. We invest together with the investor network Sciety Venture Partners, which consists of family offices, private investors, and venture capital companies. Our goal is for innovations in life science to reach their full potential, so that scientific breakthroughs in medicine and technology can become available to people around the world.

---

Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.